Infections Common in IBD, Rates Vary by Treatment
Patients with inflammatory bowel disease (IBD) experienced higher rates of mild and moderate infections. Women, smokers, those with multiple comorbidities, and those with exposure to certain IBD medications showed significantly higher rates of infections.
METHODOLOGY:
Researchers conducted a prospective observational study (June 2020 to July 2021) to evaluate the incidence of and risk factors for mild, moderate, and severe infections in 629 patients (mean age, 48.3 years; 58.2% women) with IBD who used an established remote monitoring platform for IBD management.
They used the Patient-Reported Infections Questionnaire, a validated seven-item tool with a 3-month recall period, to collect data on 15 infection categories, including respiratory tract, urinary tract, and skin conditions and COVID-19.
The presence or absence of disease activity was confirmed using a combination of monitoring questionnaire scores for patient-reported disease activity and faecal calprotectin levels.
The severity of infection was categorised on the basis of the type and route of treatment as mild (self-limiting or requiring topical treatment), moderate (requiring oral treatment), or severe (requiring hospitalisation and/or intravenous treatment).
Exposure to different medications, alone or in combination, was also assessed.
TAKEAWAY:
Overall, 991 infections were reported during 573.8 person-years of follow-up, with an overall incidence rate (IR) of 172.7 per 100 person-years, predominantly comprising mild (68%; IR, 117.5 per 100 person-years) and moderate (29.5%; IR, 50.9 per 100 person-years) infections.
Women demonstrated significantly higher rates of infections than men (IR ratio [IRR], 1.70; P < .001), with increased rates of infections among current smokers vs non-smokers (IRR, 1.43; P = .004).
Patients with a Charlson Comorbidity Index score > 2 had significantly higher rates of infections than those with lower scores (IRR for all infections, 1.69; P = .031).
Glucocorticoid use more than doubled the rates of infections (IRR, 2.02; P = .033), and compared with no treatment, the use of JAK inhibitors, immunomodulator monotherapy, anti-TNF monotherapy, and combination therapy with anti-TNF and immunomodulators were associated with increased rates of infections.
IN PRACTICE:
"Clinicians should adopt a holistic approach that includes vigilant monitoring, preferably using validated tools, such as the PRIQ [Patient-Reported Infections Questionnaire], to identify patients with frequent mild or moderate infections. In addition, proactive application of preventive strategies, like vaccination, optimizing nutritional status, counselling for lifestyle modifications, and careful selection of therapies, should be used to reduce infection risk," the authors of the study wrote.
SOURCE:
This study was led by Ashkan Rezazadeh Ardabili, MD, Department of Gastroenterology and Hepatology, Maastricht University Medical Centre+, Maastricht, the Netherlands. It was published online on July 09, 2025, in the Journal of Crohn's and Colitis.
LIMITATIONS:
The study's 1‐year follow‐up coincided with COVID‐19 public health measures, likely underestimating overall rates of infections. This study was underpowered to precisely assess rare outcomes, and its real‐world design limited the control over the distribution of medication groups, especially when stratifying the analysis by IBD subtype.
DISCLOSURES:
This study was supported in part by an investigator-initiated research grant from Takeda. Some authors reported receiving grants, non-financial support, and research prizes and serving as speaker, advisor, and/or principal investigator for various institutions and pharmaceutical companies, including Takeda.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
WebMD
5 hours ago
- WebMD
My Relationship With Medication
Medications are a must for most people with bipolar disorder, but my relationship with them hasn't been an easy one. While drugs designed to treat bipolar disorder can be very helpful, they also come with real risks, as do all medications. Anxiety about these risks has caused me to reject treatment at times. Here's what the journey has been like. Refusal I wouldn't take medication when I was first diagnosed with bipolar disorder. I didn't think I had a mental health disorder, so I simply refused to be treated for one. Unfortunately, this led to a significant decline in my functioning. Frustration Eventually, I very reluctantly agreed to take medication. I was put on a long-acting injectable (LAI). Serious side effects sent me to the emergency room. I had to wait for the drug to leave my system. I felt frustrated and helpless. I later saw a new outpatient psychiatrist. He suggested the same class of medication as the LAI, an antipsychotic, but in the form of a daily pill. I told him I didn't want to take it because I was worried about side effects. But he insisted the side effects wouldn't be as severe. Despite his reassurance, I didn't feel comfortable. I threw the pills in the garbage, but I didn't tell him that. It wasn't too long before I had a hypomanic episode. Recognizing the symptoms, I admitted to my psychiatrist that I hadn't been taking the medication he'd prescribed. He recommended starting immediately. Otherwise, I was headed for a manic episode and most likely hospitalization. I didn't want that to happen, so I took the medication. I had side effects, but I continued, driven by the fear of another manic episode and ending up in the hospital. Despite taking the medications exactly as prescribed, I eventually had another manic episode and was admitted to the hospital. Doctors there changed my treatment plan because of the side effects and the fact that the meds didn't seem to be working. That's when I started lithium. I had clients on this medication when I was a therapist, so I knew that it was an old-school medication reserved for more serious cases. But I felt pretty resigned, so I agreed to take it. Lithium requires close monitoring due to the potential for toxicity and serious side effects. As time went on, I became quite concerned about this and stopped taking it against my new psychiatrist's advice. I quickly ended up back in the hospital. Now? I take all my medications reliably. Acceptance My journey with medication has been deeply emotional, marked by anxiety and refusal. But over time, I've learned that medications are necessary for stability for me. I'm still concerned about the long-term effects of lithium. But I've been stable on it and an antipsychotic for some time. My blood is tested regularly to ensure lithium isn't at toxic levels or damaging my organs. I'm anxious about the results each time I get lab work done. Fortunately, I haven't had any issues. I hope to continue taking it for as long as I can.
Yahoo
16 hours ago
- Yahoo
Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market Report 2025: Global Trends, Revenue, and Market Dynamics
The global IBS and IBD therapeutics market is set to grow from $33.3 billion in 2025 to $52.6 billion by 2030, at a 9.6% CAGR. The report analyzes market trends, key players, and regional impact, offering insights into drug classes and business strategies of industry leaders like AbbVie and Amgen. Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The "Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market" report has been added to global market for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics is expected to grow from $33.3 billion in 2025 and is projected to reach $52.6 billion by the end of 2030, at a compound annual growth rate (CAGR) of 9.6% during the forecast period of 2025 to and IBD are types of gastrointestinal diseases. The pathophysiology of both diseases is unknown and is believed to be influenced by environmental factors, ethnicity, dietary habits and genetic predisposition. Due to varied symptoms, patients must use multiple therapeutics simultaneously. Therapeutics aim to improve patients' quality of life and achieve clinical remission for the longest period key businesses in the IBS therapeutics market include Ironwood Pharmaceuticals, AstraZeneca, AbbVie, Abbott and Allergan. In the IBD therapeutics market, corporations include AbbVie, Johnson & Johnson Services Inc., Amgen and Biogen. Start-up companies are increasingly entering the IBS and IBD therapeutics market with novel pipeline candidates. Global pharmaceutical companies, such as AbbVie and Amgen, are focused on label expansion studies and licensing collaborations with small businesses to develop and market products. Report ScopeThe report provides an overview of the global irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics market and analyzes market trends. It includes global revenue ($ million) for the base year 2024, estimated data for 2025 and forecast data from 2026 through 2030. The market is segmented into irritable bowel syndrome and inflammatory bowel disease based on disease type. The IBS therapeutics segment is further segmented based on symptom type and drug class. The IBD therapeutics segment is further segmented based on type and drug class. The report also focuses on regional market segmentation. The regions covered in this study include North America, Europe, Asia-Pacific, South America and the Middle East and Africa (MEA), focusing on significant countries in these regions. The report includes an analysis of the competitive landscape, which provides the ranking and share of key businesses in the global IBS and IBD therapeutics market. A dedicated section of company profiles providing details about leading market enterprises is also report includes: 142 data tables and 54 additional tables Analysis of the global market for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics Analyses of global market trends, with historic revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030 Estimates of the market's size and revenue prospects, along with a corresponding market share analysis by symptom type, drug class, type, and region Facts and figures pertaining to market dynamics, technological advances, regulations and the impact of macroeconomic factors Insights derived from Porter's Five Forces model, as well as global supply chain analysis Patent analysis, featuring key granted and published patents Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook Profiles of the leading companies, including AbbVie Inc., Johnson & Johnson Services Inc., Ironwood Pharmaceuticals, Takeda Pharmaceuticals, and Amgen Inc. Key Attributes: Report Attribute Details No. of Pages 155 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $33.3 Billion Forecasted Market Value (USD) by 2030 $52.6 Billion Compound Annual Growth Rate 9.6% Regions Covered Global Key Topics Covered: Chapter 1 Executive Summary Chapter 2 Market Overview Inflammatory Bowel Disease Irritable Bowel Syndrome Porter's Five Forces Analysis in the IBS and IBD Therapeutics Market Impact of U.S. Tariffs Macroeconomic Factor Analysis Population Demographics and Aging Populations Government Policies on Drug Prices Chapter 3 Market Dynamics Market Drivers Rising Prevalence of Gastrointestinal Disorders Increasing Entry of Biologics and Biosimilars Market Restraints Side Effects and Ceiling Impact of Biologics Overlap with Other Gi Disorders Use of Alternative Treatment Approaches Market Opportunities Self-Administered Drugs Personalized Therapies Chapter 4 Regulatory Landscape Regulatory Aspects of IBS and IBD Therapeutics The U.S. European Union Asia-Pacific Chapter 5 Emerging Technologies and Pipeline Analysis Key Takeaways Emerging Technologies Novel Target-based Small-Molecule Drugs Microbiome-based Therapeutics Advanced Combination Treatments AI for Drug Discovery Pipeline Analysis Chapter 6 Market Segmentation Analysis Market Analysis by Disease Irritable Bowel Syndrome Inflammatory Bowel Disease Market Analysis by Drug Class Irritable Bowel Syndrome Inflammatory Bowel Disease Market Analysis by Region North America Europe Asia-Pacific South America Middle East and Africa Chapter 7 Competitive Intelligence Key Takeaways Industry Structure Company Share Analysis of the IBD Therapeutics Market Competitive Share Analysis of the IBS Therapeutics Market Strategic Analysis Chapter 8 Sustainability in the IBS and IBD Market: An ESG Perspective Introduction to ESG ESG Risk Ratings Company Profiles Abbvie Inc. Amgen Inc. Astrazeneca Bayer AG Biogen Bristol-Myers Squibb Co. Gilead Sciences Inc. Ironwood Johnson & Johnson Services Inc. Lilly Merck & Co. Inc. Pfizer Inc. Sanofi Takeda Pharmaceutical Co. Ltd. UCB For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
2 days ago
- Medscape
Patients With IBD and PSC Face Elevated CRC Risk
TOPLINE: Patients with inflammatory bowel disease (IBD), especially those who had been diagnosed before 20 years of age, and with primary sclerosing cholangitis (PSC) had an elevated risk for colorectal cancer (CRC). METHODOLOGY: Researchers conducted a cohort study to analyse the effect of IBD with and without PSC on the risk for CRC. They enrolled patients with IBD diagnosed between January 1969 and December 2014 from the Swedish National Patient Register, including those who underwent colectomy. Patients were classified as those having PSC on the basis of the diagnosis of cholangitis. A total of 85,813 patients with IBD alone and 3066 with IBD and concomitant PSC were included. Each patient with IBD was matched with five control individuals from the general population without IBD (n = 432,037). Information on the diagnosis of CRC and cause of death was obtained using register data. Synchronous cancer was defined as two or more CRCs occurring within or less than 180 days. TAKEAWAY: Patients with IBD and concomitant PSC and those without PSC had an increased risk for CRC (incidence rate [IR], 269 and 95 cases per 100,000 person-years, respectively) compared with matched control individuals (IR, 58 cases per 100,000 person-years; P < .001). Those with unclassified IBD and PSC had the highest risk for CRC (IR ratio [IRR], 7.38; 95% CI, 5.56-9.63). Compared with control individuals, patients diagnosed with IBD before the age of 20 years, with or without PSC, demonstrated a significantly elevated risk for CRC (IRR, 74.97 and 18.75, respectively; P < .001). CRC was more likely to be in the proximal colon among patients with IBD and PSC than among those with IBD without PSC and control individuals, with 37.5% vs 27% and 22.4% of CRC being located in the caecum and ascending colon. Synchronous cancers were found in 4.7% of patients with IBD and PSC and 4.4% of those with IBD without PSC vs 1.9% of control individuals (P < .001). Those with IBD and PSC had the highest mortality (adjusted hazard ratio, 2.56; P < .001). IN PRACTICE: "In PSC+ [IBD with a concomitant PSC diagnosis], primary CRC is more often located in the proximal colon. This must be considered when counselling patients with IBD regarding type of resection for cancer and choice of restorative surgery," the authors of the study wrote. SOURCE: This study was led by Maie Abdalla, MD, PhD, Department of Surgery and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden. It was published online on July 22, 2025, in Clinical Gastroenterology and Hepatology. LIMITATIONS: The register included only hospital discharge diagnoses before 2001, potentially missing outpatients with milder disease. Variables such as diet, smoking, family history of CRC, colitis severity, tumour stage, and others could not be accounted for. PSC lacks a specific International Classification of Diseases code; therefore, researchers had to combine a cholangitis code with an IBD diagnosis to identify cases. DISCLOSURES: This study was supported by the Medical Research Council of Southeast Sweden and by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF agreement, Sweden. One author reported being an employee of AstraZeneca and having shares in the same. The author also reported receiving prior research funding and honoraria for lectures and consultancy from various pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
